Navigation Links
VaxGen Common Stock Now Quoted on OTC Bulletin Board
Date:3/14/2008

Quotation satisfies closing condition to the proposed merger with Raven

biotechnologies, inc.

SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, announced that its stock is now quoted on the OTC Bulletin Board. Punk, Ziegel and Company is the market maker and assisted VaxGen with the qualification process.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

During 2007, the company worked closely with its auditors to address outstanding accounting issues and to bring its financial reporting current by filing forms 10-K for the years ending December 31, 2004, 2005 and 2006 and the intervening forms 10-Q for those years and the first three quarters of 2007. With the company now current, and its S-4 and resale S-1 registration statements now effective, it has been cleared for OTC quotation. The company intends to seek a listing on NASDAQ or another national exchange as soon as practicable.

"We are very pleased at the achievement of this further significant milestone on the road to listing on a recognized national exchange," stated James P. Panek, VaxGen's President and CEO. "In addition to the expectation of improved liquidity for investors, this quotation satisfies the closing condition to the proposed merger between VaxGen and Raven requiring that VaxGen be listed on an approved trading market."

VaxGen's Board of Directors has set March 28th as the date for the Special Meeting of Stockholders to vote on the proposed merger.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information,
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Associates has announced the development of the Core Communications Program, ... investors, collaborators, and customers. , ... ... http://www.mainsgate.com [Mains Associates] has announced the availability of ...
... electronic properties, few layer graphene, or FLG, has emerged ... devices that incorporate the quantum effects that emerge at ... Pennsylvania have demonstrated a new method by which FLG ... thermally activated nanoparticles, a technique that results in atomically ...
... (Nasdaq: ONXX ) today announced that it ... Pharmaceuticals Conference on,Thursday, August 7, at 3:05 p.m. ... of the presentation on our website at:, http://www.onyx-pharm.com/wt/page/event_calendar ... on 15 minutes early in order to,register and ...
Cached Biology Technology:Bay-Area Company Gives Science-Based Startups a Voice 2Penn scientists carve functional nanoribbons using super-heated, nano-sized particles of iron 2
(Date:9/2/2015)... FELTON, California , September 2, 2015 /PRNewswire/ ... with the security purpose implied in a system ... hand geometry, voice, signature, iris, vein, DNA and ... crimes has forced to develop such system which ... by username, password, PIN, Patterns and tokens are ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... GSA BULLETIN articles posted online ahead of print ... Valley Antarctica; Death Valley, California, USA; Esan Volcanic Complex, ... include how melting affects granite emplacement; "how do you ... the evolution of Death Valley; and the risk of ...
... Biofuels developed from plant biomass and purpose-grown crops can ... new report says, but only through the wise allocation ... throughout the state. That,s the conclusion of "California ... the California Council on Science and Technology (CCST) co-authored ...
... a significant improvement in cardiac function after being treated with ... research, led by a team of scientists at the Buck ... tissues, providing functional insights and possible benefits for a drug ... as much as 14 percent. There are implications for human ...
Cached Biology News:7 new GSA Bulletin articles posted online ahead of print 27 new GSA Bulletin articles posted online ahead of print 37 new GSA Bulletin articles posted online ahead of print 47 new GSA Bulletin articles posted online ahead of print 57 new GSA Bulletin articles posted online ahead of print 67 new GSA Bulletin articles posted online ahead of print 7Biofuels will play integral role in California's energy future, says new EBI study 2Biofuels will play integral role in California's energy future, says new EBI study 3Lifespan-extending drug given late in life reverses age-related heart disease in mice 2
... Clone/PAD: ZMD.473. Immunogen: Synthetic ... of the mouse junctophilin-2. Specificity: ... Reactivity: Mouse (positive controls: mouse skeletal ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: